REFERENCES
1. RARE-X. The power of being counted. 2022. Available from: https://rare-x.org/case-studies/the-power-of-being-counted/ [Last accessed on 3 Jun 2024].
2. Haendel M, Vasilevsky N, Unni D, et al. How many rare diseases are there? Nat Rev Drug Discov 2020;19:77-8.
3. Garrison S, Kennedy A, Manetto N, Pariser AR, Rutter JL, Yang G. The economic burden of rare diseases: quantifying the sizeable collective burden and offering solutions. Health Affairs Forefront. 2022.
4. Tisdale A, Cutillo CM, Nathan R, et al. The IDeaS initiative: pilot study to assess the impact of rare diseases on patients and healthcare systems. Orphanet J Rare Dis 2021;16:429.
5. Navarrete-Opazo AA, Singh M, Tisdale A, Cutillo CM, Garrison SR. Can you hear us now? The impact of health-care utilization by rare disease patients in the United States. Genet Med 2021;23:2194-201.
6. Kariampuzha WZ, Alyea G, Qu S, et al. Precision information extraction for rare disease epidemiology at scale. J Transl Med 2023;21:157.
7. Zhu Q, Qu C, Liu R, et al. Rare disease-based scientific annotation knowledge graph. Front Artif Intell 2022;5:932665.
8. Lumsden JM, Urv TK. The rare diseases clinical research network: a model for clinical trial readiness. Ther Adv Rare Dis 2023;4:26330040231219272.
9. Cortese A, Zhu Y, Rebelo AP, et al. Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes. Nat Genet 2020;52:473-81.
10. Applied Therapeutics. Applied therapeutics announces initiation of registrational phase 2/3 study of AT-007 in SORD deficiency. 2021. Available from: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-initiation-registrational-phase [Last accessed on 3 Jun 2024].
11. Applied Therapeutics. Applied therapeutics announces positive sorbitol reduction data from the ongoing phase 3 INSPIRE trial in sorbitol dehydrogenase (SORD) deficiency. 2023. Available from: https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-positive-sorbitol-reduction-data
12. Nguengang Wakap S, Lambert DM, Olry A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. Eur J Hum Genet 2020;28:165-73.
13. Beaverson KL, Julkowska D, Letinturier MCV, et al. The IRDiRC chrysalis task force: making rare disease research attractive to companies. Ther Adv Rare Dis 2023;4:26330040231188979.
14. Brooks PJ, Tagle DA, Groft S. Expanding rare disease drug trials based on shared molecular etiology. Nat Biotechnol 2014;32:515-8.
15. Park JJH, Hsu G, Siden EG, Thorlund K, Mills EJ. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J Clin 2020;70:125-37.
16. Zanello G, Garrido-Estepa M, Crespo A, et al. Targeting shared molecular etiologies to accelerate drug development for rare diseases. EMBO Mol Med 2023;15:e17159.
17. Lomash RM, Shchelochkov O, Chandler RJ, Venditti CP, Pariser AR, Ottinger EA. NIH PaVe-GT Team. Successfully navigating food and drug administration orphan drug and rare pediatric disease designations for AAV9-hPCCA gene therapy: the national institutes of health platform vector gene therapy experience. Hum Gene Ther 2023;34:217-27.
19. Yu TW, Kingsmore SF, Green RC, et al. Are we prepared to deliver gene-targeted therapies for rare diseases? Am J Med Genet C Semin Med Genet 2023;193:7-12.
20. Gaviglio AM, Skinner MW, Lou LJ, Finkel RS, Augustine EF, Goldenberg AJ. Gene-targeted therapies: towards equitable development, diagnosis, and access. Am J Med Genet C Semin Med Genet 2023;193:56-63.
21. Vockley J, Aartsma-Rus A, Cohen JL, et al. Whole-genome sequencing holds the key to the success of gene-targeted therapies. Am J Med Genet C Semin Med Genet 2023;193:19-29.
